JP2017119710A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017119710A5 JP2017119710A5 JP2017061022A JP2017061022A JP2017119710A5 JP 2017119710 A5 JP2017119710 A5 JP 2017119710A5 JP 2017061022 A JP2017061022 A JP 2017061022A JP 2017061022 A JP2017061022 A JP 2017061022A JP 2017119710 A5 JP2017119710 A5 JP 2017119710A5
- Authority
- JP
- Japan
- Prior art keywords
- psychotropic drug
- flecainide
- group
- modafinil
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940001470 psychoactive drug Drugs 0.000 claims 11
- 239000004089 psychotropic agent Substances 0.000 claims 11
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 claims 8
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 8
- 229960000449 flecainide Drugs 0.000 claims 8
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 claims 6
- 229960001165 modafinil Drugs 0.000 claims 6
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 4
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims 4
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 claims 4
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims 4
- 102000002512 Orexin Human genes 0.000 claims 4
- VWYANPOOORUCFJ-UHFFFAOYSA-N alpha-Fernenol Chemical compound CC1(C)C(O)CCC2(C)C3=CCC4(C)C5CCC(C(C)C)C5(C)CCC4(C)C3CCC21 VWYANPOOORUCFJ-UHFFFAOYSA-N 0.000 claims 4
- 229940025084 amphetamine Drugs 0.000 claims 4
- 229960004823 armodafinil Drugs 0.000 claims 4
- YFGHCGITMMYXAQ-LJQANCHMSA-N armodafinil Chemical compound C=1C=CC=CC=1C([S@](=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-LJQANCHMSA-N 0.000 claims 4
- 229960001948 caffeine Drugs 0.000 claims 4
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims 4
- XNRHTMDHGDWBGP-UHFFFAOYSA-N carbamic acid;hydrochloride Chemical compound Cl.NC(O)=O XNRHTMDHGDWBGP-UHFFFAOYSA-N 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 229960000299 mazindol Drugs 0.000 claims 4
- 229960001344 methylphenidate Drugs 0.000 claims 4
- 108060005714 orexin Proteins 0.000 claims 4
- -1 pitrisant Chemical compound 0.000 claims 4
- 229960003928 sodium oxybate Drugs 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 230000003291 dopaminomimetic effect Effects 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 230000003371 gabaergic effect Effects 0.000 claims 2
- 230000000848 glutamatergic effect Effects 0.000 claims 2
- 230000000742 histaminergic effect Effects 0.000 claims 2
- 230000000862 serotonergic effect Effects 0.000 claims 2
- 206010067125 Liver injury Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- JUUFBMODXQKSTD-UHFFFAOYSA-N N-[2-amino-6-[(4-fluorophenyl)methylamino]-3-pyridinyl]carbamic acid ethyl ester Chemical compound N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 JUUFBMODXQKSTD-UHFFFAOYSA-N 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000037007 arousal Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960003667 flupirtine Drugs 0.000 claims 1
- 231100000234 hepatic damage Toxicity 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 230000008818 liver damage Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306074.9 | 2013-07-24 | ||
| EP13306074 | 2013-07-24 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016528540A Division JP6192830B2 (ja) | 2013-07-24 | 2014-07-24 | 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018233114A Division JP6694497B2 (ja) | 2013-07-24 | 2018-12-13 | 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017119710A JP2017119710A (ja) | 2017-07-06 |
| JP2017119710A5 true JP2017119710A5 (enExample) | 2017-08-17 |
| JP6453931B2 JP6453931B2 (ja) | 2019-01-16 |
Family
ID=48900920
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016528540A Expired - Fee Related JP6192830B2 (ja) | 2013-07-24 | 2014-07-24 | 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法 |
| JP2017061022A Expired - Fee Related JP6453931B2 (ja) | 2013-07-24 | 2017-03-27 | 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法 |
| JP2018233114A Expired - Fee Related JP6694497B2 (ja) | 2013-07-24 | 2018-12-13 | 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016528540A Expired - Fee Related JP6192830B2 (ja) | 2013-07-24 | 2014-07-24 | 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018233114A Expired - Fee Related JP6694497B2 (ja) | 2013-07-24 | 2018-12-13 | 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9750734B2 (enExample) |
| EP (2) | EP3024458B1 (enExample) |
| JP (3) | JP6192830B2 (enExample) |
| KR (2) | KR101754045B1 (enExample) |
| CN (1) | CN105579041B (enExample) |
| AU (1) | AU2014295030B2 (enExample) |
| BR (1) | BR112016001446A8 (enExample) |
| CA (2) | CA2997282A1 (enExample) |
| DK (1) | DK3024458T3 (enExample) |
| ES (1) | ES2661647T3 (enExample) |
| HR (1) | HRP20180487T1 (enExample) |
| HU (1) | HUE037122T2 (enExample) |
| IL (2) | IL243746A (enExample) |
| MX (2) | MX365782B (enExample) |
| PL (1) | PL3024458T3 (enExample) |
| PT (1) | PT3024458T (enExample) |
| RU (2) | RU2018122564A (enExample) |
| TR (1) | TR201802302T4 (enExample) |
| WO (1) | WO2015011246A1 (enExample) |
| ZA (1) | ZA201601146B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6720301B2 (ja) * | 2015-07-15 | 2020-07-08 | テラネクス | 脳のヘミチャネルを遮断するためのアミトリプチリンの使用及びその効果をｉｎ ｖｉｖｏで増強する方法 |
| ES3040411T3 (en) | 2018-03-22 | 2025-10-30 | Incarda Therapeutics Inc | A novel method to slow ventricular rate |
| WO2019204326A1 (en) * | 2018-04-16 | 2019-10-24 | Alsar Ltd Partnership | Compositions and methods for sustained release of flecainide |
| CA3103404A1 (en) | 2018-06-11 | 2019-12-19 | Indiana University Research And Technology Corporation | Methods for assessment and early detection of stress, selecting and monitoring treatment, and new use for drugs |
| US20190381056A1 (en) | 2018-06-17 | 2019-12-19 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
| EP3593822A1 (en) | 2018-07-13 | 2020-01-15 | Theranexus | Therapeutic and diagnostic applications of a new method of monitoring of neuroglial interaction memri) |
| US10562930B1 (en) | 2018-08-31 | 2020-02-18 | Praxis Precision Medicines, Inc. | Salts and crystal forms of GABAA positive allosteric modulator |
| US20200147093A1 (en) | 2018-10-15 | 2020-05-14 | Axsome Therapeutics, Inc. | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| US11020402B2 (en) | 2018-10-15 | 2021-06-01 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| US11021410B2 (en) * | 2018-12-10 | 2021-06-01 | Purdue Research Foundation | Layer-wise agglomerated urea granules |
| US11007185B2 (en) | 2019-08-01 | 2021-05-18 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
| US20220265666A1 (en) * | 2019-08-02 | 2022-08-25 | Praxis Precision Medicines, Inc. | Methods of treating substance abuse disorder, dyspnea, tinnitus, and child and adolescent depression |
| CN111018694A (zh) * | 2019-12-12 | 2020-04-17 | 贵州省欣紫鸿药用辅料有限公司 | 一种氟卡尼的生产方法 |
| US20230183743A1 (en) * | 2020-05-13 | 2023-06-15 | Akouos, Inc. | Compositions and methods for treating gjb2-associated hearing loss |
| KR102390194B1 (ko) * | 2020-08-03 | 2022-04-25 | 셀라이온바이오메드 주식회사 | 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물 |
| WO2022170081A1 (en) * | 2021-02-05 | 2022-08-11 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001253825A (ja) | 2000-03-13 | 2001-09-18 | Masahiko Ichimada | 帯状疱疹後神経痛用鎮痛剤 |
| US7799832B2 (en) * | 2003-10-23 | 2010-09-21 | Valeant Pharmaceuticals North America | Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains |
| US20070203079A1 (en) * | 2005-11-21 | 2007-08-30 | Caldwell Guy A | Methods of using small molecule compounds for neuroprotection |
| WO2008060622A2 (en) * | 2006-11-15 | 2008-05-22 | Coda Therapeutics, Inc. | Improved methods and compositions for wound healing |
| FR2935611B1 (fr) * | 2008-09-10 | 2010-10-15 | Commissariat Energie Atomique | Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes |
| US20130184462A1 (en) | 2010-09-30 | 2013-07-18 | Council Of Scientific & Industrial Research | Method for predicting and modeling anti-psychotic activity using virtual screening model |
| US20130096067A1 (en) | 2011-09-14 | 2013-04-18 | Norbert Perrimon | Drosophila tumor stem cell model and uses thereof |
| EP2586436A1 (en) * | 2011-10-31 | 2013-05-01 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor |
-
2014
- 2014-07-24 EP EP14742249.7A patent/EP3024458B1/en active Active
- 2014-07-24 PL PL14742249T patent/PL3024458T3/pl unknown
- 2014-07-24 WO PCT/EP2014/065975 patent/WO2015011246A1/en not_active Ceased
- 2014-07-24 HU HUE14742249A patent/HUE037122T2/hu unknown
- 2014-07-24 RU RU2018122564A patent/RU2018122564A/ru not_active Application Discontinuation
- 2014-07-24 RU RU2016105971A patent/RU2661026C2/ru active
- 2014-07-24 BR BR112016001446A patent/BR112016001446A8/pt not_active Application Discontinuation
- 2014-07-24 MX MX2016001049A patent/MX365782B/es active IP Right Grant
- 2014-07-24 KR KR1020167004739A patent/KR101754045B1/ko not_active Expired - Fee Related
- 2014-07-24 JP JP2016528540A patent/JP6192830B2/ja not_active Expired - Fee Related
- 2014-07-24 US US14/907,221 patent/US9750734B2/en not_active Expired - Fee Related
- 2014-07-24 CA CA2997282A patent/CA2997282A1/en not_active Abandoned
- 2014-07-24 PT PT147422497T patent/PT3024458T/pt unknown
- 2014-07-24 TR TR2018/02302T patent/TR201802302T4/tr unknown
- 2014-07-24 KR KR1020177015674A patent/KR20170068629A/ko not_active Ceased
- 2014-07-24 DK DK14742249.7T patent/DK3024458T3/en active
- 2014-07-24 ES ES14742249.7T patent/ES2661647T3/es active Active
- 2014-07-24 CN CN201480051866.3A patent/CN105579041B/zh not_active Expired - Fee Related
- 2014-07-24 HR HRP20180487TT patent/HRP20180487T1/hr unknown
- 2014-07-24 AU AU2014295030A patent/AU2014295030B2/en not_active Ceased
- 2014-07-24 CA CA2919140A patent/CA2919140C/en active Active
- 2014-07-24 EP EP17203646.9A patent/EP3308785A3/en not_active Withdrawn
-
2016
- 2016-01-21 IL IL243746A patent/IL243746A/en active IP Right Grant
- 2016-01-22 MX MX2019006878A patent/MX2019006878A/es unknown
- 2016-02-19 ZA ZA2016/01146A patent/ZA201601146B/en unknown
-
2017
- 2017-03-27 JP JP2017061022A patent/JP6453931B2/ja not_active Expired - Fee Related
- 2017-08-03 US US15/667,999 patent/US20180028519A1/en not_active Abandoned
- 2017-08-29 IL IL254210A patent/IL254210B/en unknown
-
2018
- 2018-09-21 US US16/138,641 patent/US10639301B2/en not_active Expired - Fee Related
- 2018-12-13 JP JP2018233114A patent/JP6694497B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017119710A5 (enExample) | ||
| RU2018122564A (ru) | Применение флекаинида в качестве антиконнексинового средства и способ потенцирования эффектов психотропных лекарственных средств | |
| HRP20210241T1 (hr) | Derivat policikličkog piridona protiv gripe i njegov predlijek | |
| SA522433000B1 (ar) | مركبات فلورو ألكيل-أوكساديازول واستخداماتها | |
| JP2016515561A5 (enExample) | ||
| FI3692040T3 (fi) | Kemiallisia yhdisteitä | |
| NZ739026A (en) | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| BR112015021027A8 (pt) | compostos terapêuticos, seus usos, e composições farmacêuticas | |
| WO2017087608A8 (en) | Modulators of ror-gamma | |
| WO2017022962A8 (ko) | Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 | |
| HUE058196T2 (hu) | N-{4-[(6,7-dimetoxikinolin-4-il)oxi]fenil}-N'-(4-fluorfenil)ciklopropán-1,1-dikarboxamid kristályos szilárd sói, elõállítási eljárások és alkalmazási eljárások | |
| HK1255500A1 (zh) | 氧固醇及其使用方法 | |
| MX2018006903A (es) | Composicion farmaceutica. | |
| WO2014172188A3 (en) | 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors | |
| ME01629B (me) | Upotreba 3,11 b-cis-dihidrotetrabenazina za tretman simptoma huntington-ove bolesti | |
| RU2018101431A (ru) | Ингибиторы индоламин-2,3-диоксигеназы | |
| WO2015173701A3 (en) | Pharmaceutical compositions comprising danirixin for treating infectious diseases | |
| JP2016537338A5 (enExample) | ||
| CO2017008115A2 (es) | Ácido (2s,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-4-(etoxioxalilamino)-2-hidroximetil-2-metilpentanoico | |
| WO2016112875A3 (zh) | 二联苯衍生物及其应用 | |
| WO2017220042A3 (zh) | 氨力农的药物组合物及其在高血压治疗中的应用 | |
| WO2015160907A3 (en) | Potent and selective inhibitors of hepatitis c virus | |
| EP2871187A4 (en) | A NEW CONNECTION OR PHARMACEUTICALALLY SALT AND PHARMACEUTICAL COMPOSITION THEREFOR AS AN ACTIVE SUBSTANCE | |
| JP2016527319A5 (enExample) | ||
| JP2018199643A5 (enExample) |